---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-002183"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:09:44.472463+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Capricor reports Q4 net loss $0.8M; Phase 3 DMD trial on track for top-line data Q4 2024

## Summary
- Q4 2023 net loss $0.8M ($0.02/share) vs $7.7M ($0.31) in Q4 2022; revenue $12.1M from Nippon Shinyaku agreement.
- Cash $39.5M at Dec 31, 2023; $10M milestone payment from Nippon Shinyaku received Jan 2024.
- Enrollment complete in Cohort A of Phase 3 HOPE-3 trial for CAP-1002 in DMD; positive interim futility analysis.
- Cohort B enrollment underway, expected to complete Q2 2024; top-line data from Cohort A expected Q4 2024.
- Selected for Project NextGen; NIAID to fund Phase 1 trial of StealthX exosome-based COVID-19 vaccine in late 2024.

## SEC filing metadata
- accession: 0001558370-24-002183
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000155837024002183/0001558370-24-002183-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000155837024002183/capr-20240229x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-002183
- JSON: https://secwatch.observer/filing/0001558370-24-002183.json
- Plain text: https://secwatch.observer/filing/0001558370-24-002183.txt

## Key facts
- Earnings Releases
  CAPRICOR THERAPEUTICS, INC. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On February 29, 2024, Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133869/000155837024002183/0001558370-24-002183-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.